U-89843A
 | |
| Legal status | |
|---|---|
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C16H23N5 |
| Molar mass | 285.395 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
U-89843A (PNU-89843) is a sedative drug which acts as an agonist at GABAA receptors, specifically acting as a positive allosteric modulator selective for the α1, α3 and α6 subtypes.[1] It has sedative effects in animals but without causing ataxia, and also acts as an antioxidant and may have neuroprotective effects.[2] It was developed by a team at Upjohn in the 1990s.[3]
References
- ^ Im HK, Im WB, Pregenzer JF, Carter DB, Hamilton BJ (December 1995). "U-89843A is a novel allosteric modulator of gamma-aminobutyric acidA receptors". The Journal of Pharmacology and Experimental Therapeutics. 275 (3): 1390–5. PMID 8531107.
- ^ Bundy GL, Ayer DE, Banitt LS, Belonga KL, Mizsak SA, Palmer JR, et al. (October 1995). "Synthesis of novel 2,4-diaminopyrrolo-[2,3-d]pyrimidines with antioxidant, neuroprotective, and antiasthma activity". Journal of Medicinal Chemistry. 38 (21): 4161–3. doi:10.1021/jm00021a004. PMID 7473542.
- ^ US 5502187, "Pharmaceutically active bicyclic-heterocyclic amines"
 | This sedative-related article is a stub. You can help Wikipedia by expanding it. |